On September 30, 2024, Invivyd, Inc., a company specializing in biotechnology with its principal executive offices located in Waltham, MA, was the subject of a Schedule 13G/A filing with the United States Securities and Exchange Commission. The filing was made by Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III, indicating a shared voting and dispositive power over 11,765,787 shares of Invivyd's common stock, which represents 9.9% of the class. The shares are held for the accounts of Maverick Capital, Ltd.'s clients. Maverick Capital, Ltd. is an investment adviser with beneficial ownership of the shares through the investment discretion it exercises over its clients' accounts. Maverick Capital Management, LLC is the General Partner of Maverick Capital, Ltd., and Mr...Show More

On September 30, 2024, Invivyd, Inc., a company specializing in biotechnology with its principal executive offices located in Waltham, MA, was the subject of a Schedule 13G/A filing with the United States Securities and Exchange Commission. The filing was made by Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III, indicating a shared voting and dispositive power over 11,765,787 shares of Invivyd's common stock, which represents 9.9% of the class. The shares are held for the accounts of Maverick Capital, Ltd.'s clients. Maverick Capital, Ltd. is an investment adviser with beneficial ownership of the shares through the investment discretion it exercises over its clients' accounts. Maverick Capital Management, LLC is the General Partner of Maverick Capital, Ltd., and Mr. Ainslie is the manager of Maverick Capital Management, LLC. The ownership reported is based on 119,442,635 outstanding shares as disclosed in Invivyd's Quarterly Report filed on August 14, 2024. The filing asserts that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Invivyd, Inc.